Findings

What do systematic reviews say?

4,710 questions · 14,842 findings · 1,394 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,880 · 19.4%GRADE not reported 1,413 · 9.5%Very low 3,103 · 20.9%Low 3,870 · 26.1%Moderate 2,663 · 17.9%High 913 · 6.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Hydroxyurea vs placebo

Pain alterationa · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 784 participants
Moderate

Hydroxyurea vs placebo

Life‐threatening illness · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 759 participants
Moderate

Hydroxyurea vs placebo

Measures of HbF · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 784 participants
Low

Hydroxyurea vs placebo

Measures of ANC · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 724 participants
Moderate

Hydroxyurea vs placebo

Health status and quality of life · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 277 participants
Low

Hydroxyurea vs placebo

Adverse events or toxicity: differences in rates of specific adverse events · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 784 participants
Low

Inhaled corticosteroids vs placebo

Combined outcome of mortality or BPD at 36 weeks' PMA · preterm infants

It is very uncertain whether inhaled corticosteroids changes combined outcome of mortality or BPD at 36 weeks' PMA compared with placebo (very low certainty).

1 finding from 1 review

Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants 2022 · Cochrane Headline outcomes only
RR 1.1 [0.74, 1.63]
1 study · 30 participants
Very low

Inhaled corticosteroids vs placebo

Mortality at 36 weeks' PMA · preterm infants

It is very uncertain whether inhaled corticosteroids changes mortality at 36 weeks' PMA compared with placebo (very low certainty).

1 finding from 1 review

Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants 2022 · Cochrane Headline outcomes only
RR 3 [0.35, 25.78]
3 studies · 61 participants
Very low

Inhaled corticosteroids vs placebo

Bronchopulmonary dysplasia/chronic lung disease · preterm infants

It is very uncertain whether inhaled corticosteroids changes BPD at 36 weeks' PMA compared with placebo (very low certainty).

1 finding from 1 review

Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants 2022 · Cochrane Headline outcomes only
RR 1 [0.59, 1.7]
1 study · 30 participants
Very low

Inhaled corticosteroids vs placebo

Open‐label use of systemic corticosteroids · preterm infants

It is very uncertain whether inhaled corticosteroids changes open‐label use of systemic corticosteroids compared with placebo (very low certainty).

1 finding from 1 review

Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants 2022 · Cochrane Headline outcomes only
RR 0.51 [0.26, 1]
4 studies · 74 participants
Very low

Alpha‐blockers vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Comparison 12: SNRIs vs placebo

Dropouts due to adverse events · adults (aged 18‐85)

It is very uncertain whether comparison 5: SNRIs changes treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.98 [0.88, 1.1]
2 studies · 687 participants
Very low

Comparison 13: SSRIs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)

Comparison 6: SSRIs probably leads to lower treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (moderate certainty).

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.66 [0.59, 0.74]
8 studies · 1078 participants
Moderate

Comparison 13: SSRIs vs placebo

Dropouts due to adverse events · adults (aged 18‐85)

Comparison 6: SSRIs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.98 [0.96, 1]
14 studies · 2399 participants
Moderate

Comparison 7: TCAs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)

Comparison 7: TCAs may leads to lower treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.6 [0.38, 0.96]
1 study · 40 participants
Low

Comparison 7: TCAs vs placebo

Dropouts due to adverse events · adults (aged 18‐85)

Comparison 7: TCAs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.92 [0.81, 1.05]
3 studies · 141 participants
Moderate

Alpha‐blockers vs placebo

Dropouts due to adverse events · adults (aged 18‐85)

Comparison 1: Alpha‐blockers showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (moderate certainty).

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.99 [0.91, 1.08]
1 study · 304 participants
Moderate

Antipsychotics vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)

It is very uncertain whether comparison 2: Antipsychotics changes treatment efficacy ‐ treatment response, as measured by the Global… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.51 [0.16, 1.67]
2 studies · 43 participants
Very low

Antipsychotics vs placebo

Dropouts due to adverse events · adults (aged 18‐85)

Comparison 2: Antipsychotics showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.98 [0.92, 1.05]
5 studies · 348 participants
Low

MAOIs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found